Key Highlights

  • NAV rose 1.51% to USD 36.69 on 29 October 2026.
  • Net Assets totalled USD 14,675,775, with 400,000 shares outstanding.
  • The fund follows an active Investment approach.
  • The SEC Yield was 0.36% as of 30 September 2026.

iShares Health Innovation Active ETF (NYSEARCA:BMED) provides exposure to innovative and emerging healthcare companies through active investment selection. On 29 October 2026, its net asset value rose by USD 0.55, or 1.51%, to USD 36.69. Net assets amounted to USD 14,675,775 on the same date, with 400,000 shares outstanding.

Research Guides Healthcare Holdings

The fund seeks total return through fundamental research into healthcare businesses. Its mandate focuses on innovation and emerging companies, allowing portfolio selection to follow an active process. The investment objective is framed around healthcare developments rather than replication of a named Equity index. The portfolio count records the number of positions without identifying individual company contributions to the daily NAV movement.

Portfolio Size and Listed Price

BMED closed at USD 36.72 on 29 October 2026 on NYSE Arca. The closing price and NAV are separately reported measures: the former records the exchange price, while the latter represents net assets per share. The fund asset classification is equity, and it uses active portfolio management. Its portfolio contained 57 holdings as of 28 October 2026. The separately disclosed non fair valued NAV was USD 36.68 as of 29 October 2026. The fund commenced on 29 September 2020. Its CUSIP identifier is 09290C400. The NAV figure and outstanding share count both relate to the same reporting date.

Income and Distribution Structure

The distribution schedule is semi-annual. The 30 day SEC yield stood at 0.36% as of 30 September 2026. This income measure is distinct from the change in NAV during a trading session. The expense ratio is 0.77%. The net expense ratio is 0.55%, separately presented from the expense ratio before applicable reductions. A distribution of USD 0.081180 per share had an ex date and Record Date of 15 June 2026 and was payable on 18 June 2026. The payment consisted entirely of income, with no short term capital gains, long term capital gains or return of capital in that distribution.

Fund Position

BMED combines its stated active mandate with semi-annual distributions and an expense ratio of 0.77%. Its October figures identify the portfolio size, share count and latest dated NAV, while the income data describe a separate aspect of the fund structure. The distribution timetable is separate from the portfolio selection process. The reported asset figure describes the fund as a whole. The share count records the number of fund shares outstanding.